Suppr超能文献

基于细胞的肝脏疾病治疗方法。

Cell-based therapy for liver diseases.

作者信息

Di Campli C, Nestola M, Piscaglia A C, Santoliquido A, Gasbarrini G, Pola P, Gasbarrini A

机构信息

Istituto di Medicina Interna e Geriatria, Università Cattolica del Sacro Cuore, Policlinico Gemelli - Roma, Italy.

出版信息

Eur Rev Med Pharmacol Sci. 2003 Mar-Apr;7(2):41-4.

Abstract

Although liver transplantation has become standard therapy in the treatment of patients with liver failure, several problems should be considered in the management of these patients. Other approaches have been proposed, in particular cellular-based procedures. Isolated hepatocytes may be used instead of whole organ transplantation or integrated within the bioartificial devices, in order to replace the missing synthetic and metabolic liver functions. Moreover patient's own hepatocytes may be ex vivo genetically modified to provide the function of a mutant gene. However, new cell sources alternative to adult hepatocytes are actually under investigation, on the basis of recent advances in the field of liver repopulation. Xenogenic primary cells, human hepatoma cells, immortalized hepatocytes and stem cells have been testing in several experiments, even if up to now none of them represent a "gold-standard" for cell-based treatment of liver diseases. In the next future, it is possible that different clinical situations will require different therapeutic approaches, that will be finally defined from the concomitant advances in the development of artificial devices and liver cell biology.

摘要

尽管肝移植已成为治疗肝衰竭患者的标准疗法,但在管理这些患者时仍应考虑几个问题。已经提出了其他方法,特别是基于细胞的程序。可以使用分离的肝细胞代替全器官移植或整合到生物人工装置中,以替代缺失的肝脏合成和代谢功能。此外,患者自身的肝细胞可以在体外进行基因改造,以提供突变基因的功能。然而,基于肝脏再生领域的最新进展,目前正在研究替代成人肝细胞的新细胞来源。异种原代细胞、人肝癌细胞、永生化肝细胞和干细胞已经在多个实验中进行了测试,尽管到目前为止,它们中没有一个代表基于细胞的肝病治疗的“金标准”。在不久的将来,不同的临床情况可能需要不同的治疗方法,这些方法最终将由人工装置和肝细胞生物学发展的同步进展来确定。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验